Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis
暂无分享,去创建一个
R. Terracciano | N. Lombardo | A. Vatrella | L. Gallelli | C. Pelaia | C. Tinello | A. Maglio | G. Pelaia
[1] M. Triggiani,et al. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps , 2023, Frontiers in Immunology.
[2] H. Hammad,et al. Lung epithelial cells: upstream targets in type 2-high asthma. , 2023, European Journal of Immunology.
[3] M. D’Amato,et al. Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study , 2023, International journal of molecular sciences.
[4] T. Hackett,et al. Airway remodeling heterogeneity in asthma and its relationship to disease outcomes , 2023, Frontiers in Physiology.
[5] E. Heffler,et al. Exhaled nitric oxide in asthma: from diagnosis to management , 2022, Current opinion in allergy and clinical immunology.
[6] K. Matsunaga,et al. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. , 2022, Allergology international : official journal of the Japanese Society of Allergology.
[7] C. Brightling,et al. Human Lung Mast Cells: Therapeutic Implications in Asthma , 2022, International journal of molecular sciences.
[8] S. Wise,et al. Unified Airway Disease: Examining Prevalence and Treatment of Upper Airway Eosinophilic Disease with Comorbid Asthma. , 2022, Otolaryngologic clinics of North America.
[9] S. Reitsma,et al. Unified Airway Disease: A Contemporary Review and Introduction. , 2022, Otolaryngologic clinics of North America.
[10] E. Shamil,et al. Unified Airway Disease: Medical Management. , 2022, Otolaryngologic clinics of North America.
[11] N. Hizawa. The understanding of asthma pathogenesis in the era of precision medicine. , 2022, Allergology international : official journal of the Japanese Society of Allergology.
[12] J. Boyce,et al. Updates on immune mechanisms in aspirin-exacerbated respiratory disease. , 2022, The Journal of allergy and clinical immunology.
[13] C. Vitale,et al. Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma , 2022, Biomedicines.
[14] A. Yorgancioglu,et al. Type 2 inflammation in asthma and other airway diseases , 2022, ERJ Open Research.
[15] J. Lim,et al. Distinct subsets of innate lymphoid cells in nasal polyp. , 2022, Allergology international : official journal of the Japanese Society of Allergology.
[16] F. Schleich,et al. Biological Therapy of Severe Asthma and Nasal Polyps , 2022, Journal of personalized medicine.
[17] V. Seccia,et al. S. aureus and IgE-mediated diseases: pilot or copilot? A narrative review , 2022, Expert review of clinical immunology.
[18] R. Terracciano,et al. Novel Biological Therapies for Severe Asthma Endotypes , 2022, Biomedicines.
[19] H. Hammad,et al. Emerging Paradigms in Type 2 Immunity. , 2022, Annual review of immunology.
[20] I. Pavord,et al. Asthma remission: what is it and how can it be achieved? , 2022, European Respiratory Journal.
[21] G. Canonica,et al. Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets , 2022, Frontiers in Pharmacology.
[22] S. Yancey,et al. The roles of eosinophils and interleukin‐5 in the pathophysiology of chronic rhinosinusitis with nasal polyps , 2022, International forum of allergy & rhinology.
[23] G. Canonica,et al. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study , 2022, Respiratory Research.
[24] L. Bacharier,et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. , 2021, The New England journal of medicine.
[25] G. E. Carpagnano,et al. Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy , 2021, Biomedicines.
[26] M. Triggiani,et al. Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma , 2021, Biomedicines.
[27] E. Bel,et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. , 2021, The Lancet. Respiratory medicine.
[28] M. D’Amato,et al. Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[29] I. Pavord,et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. , 2021, The Lancet. Respiratory medicine.
[30] C. Bachert,et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. , 2021, The Journal of allergy and clinical immunology.
[31] A. Peters,et al. Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches , 2021, Allergy.
[32] N. Lombardo,et al. Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis , 2021, Journal of asthma and allergy.
[33] F. Bureau,et al. Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity? , 2021, International journal of molecular sciences.
[34] M. D’Amato,et al. Benralizumab effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicentre Study. , 2021, The journal of allergy and clinical immunology. In practice.
[35] I. Pavord,et al. From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases , 2021, Allergy.
[36] C. Akdis,et al. Cellular and molecular mechanisms of allergic asthma. , 2021, Molecular aspects of medicine.
[37] A. Shalek,et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. , 2021, The Journal of allergy and clinical immunology.
[38] B. Beghé,et al. Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program , 2021, Journal of asthma and allergy.
[39] M. D’Amato,et al. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study , 2021, Therapeutic advances in respiratory disease.
[40] S. Yancey,et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Respiratory medicine.
[41] P. Gevaert,et al. Mepolizumab for chronic rhinosinusitis with nasal polyps. , 2021, The Lancet. Respiratory medicine.
[42] C. Bachert,et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. , 2021, Rhinology.
[43] M. Fux,et al. Basophils Orchestrating Eosinophils’ Chemotaxis and Function in Allergic Inflammation , 2021, Cells.
[44] A. Matucci,et al. Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses? , 2021, International journal of molecular sciences.
[45] W. Busse,et al. What is the contribution of IgE to nasal polyposis? , 2021, The Journal of allergy and clinical immunology.
[46] H. Hammad,et al. The basic immunology of asthma , 2021, Cell.
[47] A. McKenzie,et al. Group 2 Innate Lymphoid Cells: Team Players in Regulating Asthma. , 2021, Annual review of immunology.
[48] M. D’Amato,et al. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression , 2021, Journal of asthma and allergy.
[49] G. Canonica,et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. , 2020, The Lancet. Respiratory medicine.
[50] T. Hill,et al. Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice. , 2020, Chest.
[51] L. Yarmus,et al. Sex differences in M2 polarization, chemokine and IL-4 receptors in monocytes and macrophages from asthmatics. , 2020, Cellular immunology.
[52] Matucci Andrea,et al. The emerging role of type 2 inflammation in asthma , 2020, Expert review of clinical immunology.
[53] L. James,et al. Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy , 2020, Drug design, development and therapy.
[54] M. Rådinger,et al. The Airway Epithelium—A Central Player in Asthma Pathogenesis , 2020, International journal of molecular sciences.
[55] M. Maniscalco,et al. Basophil activation test for Staphylococcus aureus enterotoxins in severe asthmatic patients , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[56] J. Mullol,et al. Chronic Rhinosinusitis With Nasal Polyps and Asthma. , 2020, The journal of allergy and clinical immunology. In practice.
[57] A. Douiri,et al. Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. , 2020, Chest.
[58] P. Howarth,et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis , 2020, European Respiratory Journal.
[59] A. Kato,et al. Group 2 innate lymphoid cells in nasal polyposis. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[60] N. Lombardo,et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma , 2020, International journal of immunopathology and pharmacology.
[61] D. Wang,et al. Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation , 2020, Allergy.
[62] R. Terracciano,et al. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[63] C. Bachert,et al. Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. , 2020, The Journal of allergy and clinical immunology.
[64] G. Passalacqua,et al. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. , 2020, Respiratory medicine.
[65] A. Didier,et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[66] A. Moreira,et al. FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma , 2020, Journal of asthma and allergy.
[67] E. Heffler,et al. Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[68] K. Nakagome,et al. Mechanisms of eosinophilic inflammation , 2020, Asia Pacific allergy.
[69] Huaxi Xu,et al. Alternatively activated macrophages; a double-edged sword in allergic asthma , 2020, Journal of Translational Medicine.
[70] W. Fokkens. EPOS2020: a major step forward. , 2020, Rhinology.
[71] A. Peters,et al. Utilizing Endotypes, Phenotypes, and Inflammatory Markers to Guide Treatment Decisions in Chronic Rhinosinusitis. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[72] N. Scichilone,et al. Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. , 2020, Pulmonary pharmacology & therapeutics.
[73] T. Chatila,et al. Mechanisms of Dupilumab , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[74] Hae‐Sim Park,et al. Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma , 2020, Allergy.
[75] G. Canonica,et al. Interleukin-5 in the Pathophysiology of Severe Asthma , 2019, Front. Physiol..
[76] F. Granata,et al. The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma , 2019, Front. Pharmacol..
[77] P. Nair,et al. Eosinophilic Asthma. , 2019, The journal of allergy and clinical immunology. In practice.
[78] C. Bachert,et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials , 2019, The Lancet.
[79] P. Hellings,et al. Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. , 2019, The Journal of allergy and clinical immunology.
[80] Jianbo Shi,et al. Concordant systemic and local eosinophilia relates to poorer disease control in patients with nasal polyps , 2019, The World Allergy Organization journal.
[81] R. Terracciano,et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. , 2019, Pulmonary pharmacology & therapeutics.
[82] H. Ortega,et al. Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.
[83] H. Hammad,et al. The Cytokines of Asthma. , 2019, Immunity.
[84] R. Savino,et al. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study. , 2019, Pulmonary pharmacology & therapeutics.
[85] J. Dalphin,et al. Omalizumab's effectiveness in severe allergic asthma and nasal polyps: a real-life study. , 2019, Journal of investigational allergology & clinical immunology.
[86] H. Makita,et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. , 2019, The Lancet. Respiratory medicine.
[87] G. Canonica,et al. The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials , 2018, The World Allergy Organization journal.
[88] R. Terracciano,et al. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study. , 2018, Pulmonary pharmacology & therapeutics.
[89] R. Terracciano,et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness , 2018, Therapeutic advances in respiratory disease.
[90] P. Nair,et al. Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma. , 2018, Immunology and allergy clinics of North America.
[91] D. Wang,et al. Role of IL‐13Rα2 in modulating IL‐13‐induced MUC5AC and ciliary changes in healthy and CRSwNP mucosa , 2018, Allergy.
[92] I. Pavord,et al. Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.
[93] K. Rabe,et al. Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.
[94] R. Terracciano,et al. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma , 2018, BioMed research international.
[95] Min-Hye Kim,et al. Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[96] R. Terracciano,et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy , 2018, Drug design, development and therapy.
[97] E. Hoffman,et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction , 2018, The Journal of clinical investigation.
[98] M. Kraft,et al. Eosinophilic and Noneosinophilic Asthma , 2018, American journal of respiratory and critical care medicine.
[99] R. Savino,et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab , 2017, Drug design, development and therapy.
[100] R. Terracciano,et al. Dupilumab for the treatment of asthma , 2017, Expert opinion on biological therapy.
[101] C. Bachert,et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial , 2017, The Journal of allergy and clinical immunology.
[102] L. Macchia,et al. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. , 2017, Respiratory medicine.
[103] C. Akdis,et al. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells , 2017, Immunological reviews.
[104] E. Kerwin,et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Respiratory medicine.
[105] A. Menzies-Gow,et al. The Biology of Eosinophils and Their Role in Asthma , 2017, Front. Med..
[106] G. Canonica,et al. Targeted therapy in severe asthma today: focus on immunoglobulin E , 2017, Drug design, development and therapy.
[107] M. Johansson. Eosinophil Activation Status in Separate Compartments and Association with Asthma , 2017, Front. Med..
[108] K. Rabe,et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.
[109] F. Albers,et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.
[110] G. Brusselle,et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. , 2017, Pulmonary pharmacology & therapeutics.
[111] C. Galeone,et al. Real-life Efficacy of Omalizumab After 9 Years of Follow-up , 2017, Allergy, asthma & immunology research.
[112] G. Canonica,et al. Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? , 2017, Front. Immunol..
[113] Hongwei H Zhang,et al. Interleukin-4 Inhibits Regulatory T Cell Differentiation through Regulating CD103+ Dendritic Cells , 2017, Front. Immunol..
[114] R. Schleimer. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. , 2017, Annual review of pathology.
[115] J. Fahy,et al. Claudin‐18 deficiency is associated with airway epithelial barrier dysfunction and asthma , 2017, The Journal of allergy and clinical immunology.
[116] E. Bleecker,et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.
[117] W. Busse,et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.
[118] C. Lemière,et al. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. , 2016, Chest.
[119] H. Ortega,et al. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. , 2016, Clinical therapeutics.
[120] M. Preianò,et al. Role of biologics in severe eosinophilic asthma – focus on reslizumab , 2016, Therapeutics and clinical risk management.
[121] D. Erle,et al. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. , 2016, The Journal of clinical investigation.
[122] C. Bachert,et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. , 2016, The Journal of allergy and clinical immunology.
[123] J. Mullol,et al. Nasal polyps in patients with asthma: prevalence, impact, and management challenges , 2016, Journal of asthma and allergy.
[124] J. Boyce,et al. Aspirin-Exacerbated Respiratory Disease--New Prime Suspects. , 2016, The New England journal of medicine.
[125] E. R. Sutherland,et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. , 2016, JAMA.
[126] S. Brody,et al. IL13 activates autophagy to regulate secretion in airway epithelial cells , 2016, Autophagy.
[127] S. Durham,et al. Asthma phenotypes and IgE responses , 2016, European Respiratory Journal.
[128] G. Yancopoulos,et al. Targeting key proximal drivers of type 2 inflammation in disease , 2015, Nature Reviews Drug Discovery.
[129] A. Getz,et al. Clinical Examination of Tissue Eosinophilia in Patients with Chronic Rhinosinusitis and Nasal Polyposis , 2014, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[130] L. Konge,et al. Airway Inflammation in Chronic Rhinosinusitis with Nasal Polyps and Asthma: The United Airways Concept Further Supported , 2015, PloS one.
[131] E. Bateman,et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.
[132] R. Schleimer,et al. Pathogenesis of nasal polyposis , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[133] R. Terracciano,et al. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments. , 2015, Current Drug Targets.
[134] Ian D Pavord,et al. Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.
[135] I. Pavord,et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.
[136] P. Ilmarinen,et al. Regulation of Spontaneous Eosinophil Apoptosis—A Neglected Area of Importance , 2014, Journal of cell death.
[137] J. Corren. Role of Interleukin-13 in Asthma , 2013, Current Allergy and Asthma Reports.
[138] J. Mullol,et al. Chronic rhinosinusitis with and without nasal polyps and rhinitis in adult asthma. Frequency distribution and relationship with asthma control and severity (the IRIS-ASMA study) , 2013 .
[139] M. Kraft,et al. Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-&bgr;1 in airway fibroblasts in asthma , 2013, European Respiratory Journal.
[140] J. Mullol,et al. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. , 2013, Immunology and allergy clinics of North America.
[141] S. Georas,et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells , 2013, Tissue barriers.
[142] M. Rothenberg,et al. Targeting eosinophils in allergy, inflammation and beyond , 2013, Nature Reviews Drug Discovery.
[143] A. Peters,et al. Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. , 2013, American journal of respiratory and critical care medicine.
[144] Ian D Pavord,et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.
[145] L. Boulet,et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.
[146] J. Bousquet,et al. Clinical Benefits of 7 Years of Treatment with Omalizumab in Severe Uncontrolled Asthmatics , 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.
[147] J. Castro‐Rodriguez,et al. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. , 2011, Chest.
[148] Calman Prussin,et al. IgE, mast cells, basophils, and eosinophils. , 2003, The Journal of allergy and clinical immunology.
[149] G. Kaiko,et al. Immunological decision‐making: how does the immune system decide to mount a helper T‐cell response? , 2008, Immunology.
[150] O. Zetterström,et al. Apoptotic eosinophils in sputum from asthmatic patients correlate negatively with levels of IL-5 and eotaxin. , 2007, Respiratory medicine.
[151] S. Phipps,et al. Eosinophil trafficking in allergy and asthma. , 2007, The Journal of allergy and clinical immunology.
[152] Reynold A Panettieri,et al. Asthma , 1894, Annals of Internal Medicine.
[153] J Bousquet,et al. Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.
[154] R. Geha,et al. The regulation of immunoglobulin E class-switch recombination , 2003, Nature Reviews Immunology.
[155] Choon-Sik Park,et al. Association of Interleukin-5 and Eotaxin with Acute Exacerbation of Asthma , 2003, International Archives of Allergy and Immunology.
[156] D. Postma,et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.
[157] K. Rabe,et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. , 2002, The Journal of allergy and clinical immunology.
[158] R. Homer,et al. Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1 , 2001, The Journal of experimental medicine.
[159] P. Foster,et al. The Effect of IL-5 and Eotaxin Expression in the Lung on Eosinophil Trafficking and Degranulation and the Induction of Bronchial Hyperreactivity1 , 2000, The Journal of Immunology.
[160] C. Bachert,et al. IL-5 synthesis is upregulated in human nasal polyp tissue. , 1997, The Journal of allergy and clinical immunology.
[161] C. Bachert,et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. , 1997, Journal of immunology.
[162] M. Jordana,et al. Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. , 1996, American journal of respiratory cell and molecular biology.
[163] A. Ponticiello,et al. Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthmi , 1996, Allergy.